Trials / Recruiting
RecruitingNCT06727981
First-Line and Neoadjuvant Immunotherapy for Gastric Cancer
Prospective Cohort Study on the Efficacy, Adverse Effects, and Biomarkers of First-Line/Neoadjuvant Therapy With Immune Checkpoint Inhibitors Combined With Chemotherapy in Advanced Gastric Cancer
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 500 (estimated)
- Sponsor
- Qilu Hospital of Shandong University · Academic / Other
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
This prospective observational study aims to evaluate the efficacy and safety of immune checkpoint inhibitors as first-line and neoadjuvant therapy for advanced gastric cancer, while also investigating relevant biomarkers to better understand their role in immunotherapy outcomes
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ICI plus Chemothearpy | This intervention involves the administration of immune checkpoint inhibitors (ICIs) in combination with standard chemotherapy. |
| DRUG | Chemotherapy | This intervention involves the administration of standard chemotherapy alone. |
Timeline
- Start date
- 2022-01-15
- Primary completion
- 2027-01-15
- Completion
- 2028-01-15
- First posted
- 2024-12-11
- Last updated
- 2024-12-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06727981. Inclusion in this directory is not an endorsement.